On January 7, Argo Biopharma announced that it had entered into two exclusive license cooperation agreements with Novartis for RNAi therapies.Argo will receive an upfront payment of $185 million from Novartis and is eligible for potential option and milestone payments, as well as tiered royalties on commercial sales.The Potential Total Value of the Two Transactions Reaches Up to 4.165 Billion US Dollars.Under the first agreement, Argo exclusively licensed the global development and commercialization rights of a Phase I clinical product for cardiovascular diseases to Novartis. In addition, Novartis will also obtain potential license options for up to two additional targets of compounds targeting cardiovascular diseases.According to the second agreement, Argo exclusively licensed the development and commercialization rights outside of Greater China for a Phase I/IIa clinical stage project used in the treatment of cardiovascular diseases to Novartis.These clinical-stage assets were all discovered and developed by Argo using its RNAi technology platform.
Argo Biopharma was founded in April 2021, focusing on the development of siRNA drugs. Its team has many years of professional experience in all aspects of RNAi drug development, including nucleic acid sequence design, chemical modification, GalNAc delivery technology, extrahepatic tissue-targeted delivery technology, oligonucleotide synthesis, and CMC. The company has established a complete nucleic acid drug development platform.Source: Argo's official websiteCurrently, Argo has built a rich and differentiated product pipeline around cardiovascular diseases, rare diseases, viral infections, metabolic diseases, and central nervous system diseases.
Source:Argo Biopharma Official WebsiteCopyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
